Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2023 | Practical considerations for genomic testing in colorectal cancer

Stacey Cohen • 20 Jan 2023
ASCO GI 2023
Colorectal Cancer Gastrointestinal Cancer

Stacey Cohen, MD, Fred Hutchinson Cancer Center, Seattle, WA, comments on how genomic testing for molecular aberrations can influence treatment approaches in colorectal cancer. Liquid biopsies enable monitoring of multiple ctDNA mutations of varying frequencies, which can ultimately inform clinicians when a treatment regimen should be changed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ

More from Stacey Cohen

0:31
Highlights in colorectal cancer at ASCO GI 2023
Stacey Cohen • 20 Jan 2023
2:17
Does postoperative cfDNA affect MRD detection rates in CRC?
Stacey Cohen • 20 Jan 2023
0:31
Applications of ctDNA in the management of colorectal cancer
Stacey Cohen • 20 Jan 2023
0:53
Will ctDNA replace traditional pathological markers?
Stacey Cohen • 12 Sep 2022

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals